BTC iShares Core High Dividend ETF

Most Recent

  • uploads///Merck
    Company & Industry Overviews

    Merck’s Stock Price Has Increased ~34% in 2018

    On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.

    By Daniel Collins
  • uploads///capsule _
    Company & Industry Overviews

    How Wall Street Analysts View Merck

    On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What’s Pfizer’s Current Valuation?

    Pfizer is trading at a forward PE ratio of ~14.5x on October 18—compared to the industry average of ~15.7x.

    By Mike Benson
  • uploads///Merck earnings
    Earnings Report

    What’s Expected for Merck’s Q3 2018 Earnings

    Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Pfizer’s Dividend Growth Trend and Analysts’ Recommendations

    Wall Street analysts expect Pfizer’s (PFE) November dividend to be ~$0.33 and for its quarterly dividend for 2019 to be $0.36.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Elanco, Eli Lilly’s Animal Health Business

    Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.

    By Mike Benson
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Eli Lilly’s Stock Performance in September

    Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Pfizer’s Market Cap and Shareholding Pattern

    The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Eli Lilly’s Neuroscience Products in Q2 2018

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes neuroscience products such as Cymbalta, Strattera, and Zyprexa.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    These Products Saw Falling Sales in Pfizer’s Q2 2018

    Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lily Highlights Study Results of Emgality for Migraines

    Emgality is presently under review by the US Food and Drug Administration for migraine prevention.

    By Mike Benson
  • uploads///cons non cycl
    Consumer

    What’s the Dividend Yield of the Consumer Non-Cyclical Sector?

    The consumer non-cyclical segment recorded a dividend yield of 3%.

    By Amanda Lawrence
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Post-1Q18 Valuation

    In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.

    By Mike Benson
  • uploads///div pri d
    Energy & Utilities

    Factors that Could Drive Dominion Energy’s Dividend Growth

    Dominion Energy’s (D) present dividend yield of 4.4% is due to its dividend growth and price loss.

    By Amanda Lawrence
  • uploads///div pri gro khc
    Consumer

    Why The Kraft Heinz Company’s Outlook Still Seems Promising

    The Kraft Heinz Company’s (KHC) net sales grew 44% in 2016 before falling 1% in 9M17. Every product category drove the growth in 2016, offset by a decline in the infant and nutrition segments.

    By Amanda Lawrence
  • uploads///Graph
    Company & Industry Overviews

    Xtandi’s Prescription Volumes Continue to Rise in 2017

    In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.

    By Margaret Patrick
  • uploads///REV EPS FB
    Tech & Comm Services

    How Facebook Compares to Broad Indexes

    Facebook (FB) revenues rose 54% and 47% in 2016 and 9M17, respectively.

    By Amanda Lawrence
  • uploads///Chart  ICR
    Company & Industry Overviews

    Merck’s Immunology and Cardiovascular Franchise in 3Q17

    In 3Q17, Merck’s Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    Merck & Co.’s Valuation in November 2017

    Merck & Co. (MRK) reported EPS of $1.11 on revenues of $10.3 billion in 3Q17, which was a 2% fall compared to EPS of $1.07 on revenues of $10.5 billion in 3Q16.

    By Mike Benson
  • uploads///REV EPS DVN
    Energy & Utilities

    Analyzing Devon Energy, a Low Dividend Grower

    Devon Energy’s (DVN) revenues fell 36.0% and 7.0% in 2015 and 2016, respectively.

    By Amanda Lawrence
  • uploads///REV EPS GLW
    Tech & Comm Services

    A Look at Corning, Another Top Dividend Grower

    Corning’s net sales and earnings in 2015 and 2016 Corning’s (GLW) net sales fell 6% in 2015 before rising 3% in 2016. Its North American net sales rose in 2015 before falling slightly in 2016, and its Asia-Pacific, European, and other net sales fell in 2015 and rose in 2016. In 2015, its Optical Communications segment’s net sales […]

    By Amanda Lawrence
  • uploads///Chart  NGC
    Earnings Report

    These Pfizer Products Lost Market Share in 3Q17

    BeneFIX revenues fell 14% to $151 million during 3Q17, driven by a 16% fall in international sales to $87 million.

    By Mike Benson
  • uploads///Chart
    Consumer

    What Do Analysts Think about Merck?

    Wall Street analysts estimate Merck’s (MRK) top line will increase marginally by 0.1% to ~$10,546 million in 3Q17.

    By Mike Benson
  • uploads///dividend
    Earnings Report

    A Look at American Airlines’ Dividend Payouts

    Only four airlines—Delta Air Lines (DAL), Southwest Airlines (LUV), American Airlines (AAL), and Alaska Air Group (ALK)—pay dividends to investors.

    By Ally Schmidt
  • uploads///Dividend yield
    Earnings Report

    Delta Air Lines Increased Dividend Payout in 3Q17

    Delta Air Lines (DAL) increased its dividend payout 50.0% in 3Q17, resulting in ~$0.31 dividend per share. At that rate, DAL has an indicated dividend yield of 2.3%.

    By Ally Schmidt
  • uploads///DJIA TAX DIV
    Miscellaneous

    How Dividend Yields of DJIA Stocks in Top Tax Bracket Stack Up

    This series will discuss some of the Dow Jones Industrial Average (or DJIA) companies in the highest income tax bracket and their corresponding dividend yields.

    By Amanda Lawrence
  • uploads///Chart  SWR
    Company & Industry Overviews

    Assessing Pfizer’s Performance by Business Segment in 2Q17

    Pfizer’s Innovative Health segment contributed ~59% of PFE’s total revenues in 2Q17, and analysts expect the contribution to rise to ~60% in 3Q17.

    By Mike Benson
  • uploads///BLK
    Financials

    What Led to BlackRock’s Downward Sloping Dividend Yield Curve?

    BlackRock posted a 7.0% revenue growth in the first half of 2017, driven by every segment except multi-asset and alternatives, which reported flat growth.

    By Amanda Lawrence
  • uploads///HP PRICE
    Energy & Utilities

    Decoding Helmerich & Payne’s Dividend Yield

    What’s driving Helmerich & Payne’s high yield? Contract oil and gas well driller Helmerich & Payne (HP) recorded a sharp drop in its 2016 operating revenue due to declines in its US drilling, offshore, and international segments. Its revenue fell 19% in 2015, compared with 51% in 2016. Its operating income, as a result, ended […]

    By Amanda Lawrence
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///DY PG
    Consumer

    Dividend Yield of Procter & Gamble

    Procter & Gamble’s (PG) PE ratio of 25.1x compares to a sector average of 23.3x. The dividend yield of 3.0% compares to a sector average of 3.8%.

    By Amanda Lawrence
  • uploads///EDVS
    Energy & Utilities

    Consolidated Edison’s Dividend Trajectory

    Consolidated Edison’s (ED) 2016 operating revenues fell 4.0% due to a decline in every segment; namely, electric, gas, steam, and non-utility.

    By Amanda Lawrence
  • uploads///Chart  OtherDev
    Company & Industry Overviews

    Pfizer’s Corporate and Pipeline Developments in 2Q17

    Apart from Pfizer’s (PFE) product developments, let’s take a look at some recent pipeline and corporate developments.

    By Mike Benson
  • uploads///JNJ
    Healthcare

    Has Johnson & Johnson Been Able to Increase Dividends?

    Johnson & Johnson’s (JNJ) EPS (earnings per share) for the first half of 2017 fell 0.70%, driven by higher selling, marketing, and administrative and R&D expenses.

    By Amanda Lawrence
  • uploads///Biosimilars revenues
    Company & Industry Overviews

    Pfizer Sees a Significant Opportunity in This for Revenue Growth

    In 2016, Pfizer’s (PFE) biosimilar business reported revenues of ~$319 million, compared with $63 million in 2015.

    By Daniel Collins
  • uploads///Dividend
    Earnings Report

    Can Delta Continue to Be the Best Airline Dividend Payer?

    Delta Air Lines (DAL) has an indicated dividend yield of 2.0%, the highest among the four airlines that pay dividends.

    By Ally Schmidt
  • uploads///mcy
    Miscellaneous

    The Top Dividend-Growing Financial Sector Stocks

    Mercury General (MCY) has consistently recorded revenue growth since fiscal 2011, except for a minor decline in fiscal 2015

    By Amanda Lawrence
  • uploads///ibm
    Miscellaneous

    IBM’s Dividend Growth Curve

    For IBM (IBM), 1Q17 marked the 22nd year of annual dividend growth despite being the 20th successive quarter with no revenue growth.

    By Amanda Lawrence
  • uploads///Chart  ICR
    Company & Industry Overviews

    Merck’s Immunology and Cardiovascular Franchise in 1Q17

    The combined revenues for Zetia and Vytorin fell 35% to $575 million in 1Q17, compared to $889 million in 1Q16.

    By Mike Benson
  • uploads///Chart  Rev Brkup
    Company & Industry Overviews

    Pfizer’s Segment Performance in 1Q17

    Pfizer Innovative Health contributed $7.4 billion, or about 58.0% of Pfizer’s total revenues in 1Q17.

    By Mike Benson
  • uploads///sectorpricemovt
    Miscellaneous

    Comparing Growth and Value Stock Sectors

    The SPDR S&P 500 Growth ETF (SPYG) has generated a YTD return of 13.3% versus 4.3% from the SPDR S&P 500 Value ETF (SPYV).

    By Amanda Lawrence
  • uploads///Chart  Rev Brkup
    Company & Industry Overviews

    Understanding Pfizer’s 1Q17 Performance by Geography

    Pfizer (PFE) reported a 2% decline in revenues to ~$12.8 billion for 1Q17, as compared to $13.0 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Segment
    Company & Industry Overviews

    Eli Lilly’s Business Segments’ Performance in 1Q17

    Elanco, Eli Lilly’s Animal Health business, reported growth of 2% to $769.4 million during 1Q17.

    By Mike Benson
  • uploads///Div yields
    Company & Industry Overviews

    TOT, SU, E, and PBR: Comparing Their Dividend Yields

    Total (TOT), Suncor Energy (SU), ENI (E), and Petrobras (PBR) have provided steady returns to their shareholders in the form of dividends.

    By Maitali Ramkumar
  • uploads///Cashflows
    Company & Industry Overviews

    Is BP’s Cash Flow Slated for Growth?

    Rising oil prices have given BP some hope that its cash flows could improve. The robust upstream project pipeline is also likely to result in higher production.

    By Maitali Ramkumar
  • uploads///Div yield
    Company & Industry Overviews

    Who Has Higher Dividend Yields: RDS.A, XOM, CVX, or BP?

    Shell has the highest dividend yield of 7.1% among the integrated energy stocks we’re covering in this series.

    By Maitali Ramkumar
  • uploads///Chart  Animal
    Earnings Report

    Performance of Eli Lilly & Co.’s Elanco in 1Q17

    Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.

    By Mike Benson
  • uploads///Chart  Endocrine
    Earnings Report

    Eli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products

    Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues.

    By Mike Benson
  • uploads///Div yield
    Company & Industry Overviews

    Inside Integrated Energy’s Dividend Yields: Comparing XOM, CVX, RDS.A, and BP

    ExxonMobil (XOM), Chevron (CVX), Royal Dutch Shell (RDS.A), and BP (BP) have consistently given returns to shareholders in the form of dividends.

    By Maitali Ramkumar
  • uploads///Div yield
    Company & Industry Overviews

    TOT, SU, E, PBR: Who Has Highest Dividend Yield?

    Total (TOT), Suncor Energy (SU), ENI (E), and Petrobras (PBR) have consistently given returns to shareholders in the form of dividends.

    By Maitali Ramkumar
  • uploads///Div yields
    Company & Industry Overviews

    Integrated Energy Stocks: Who Stands Tall in Dividend Yield?

    Shell’s dividend yield is 7.1%, the highest among the integrated energy stocks in this series.

    By Maitali Ramkumar
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Wall Street Analysts Are Saying about Eli Lilly

    Eli Lilly (LLY) reported EPS (earnings per share) of $2.58 on revenue of $21.2 billion in 2016, compared to EPS of $2.26 on revenue of $20.0 million in 2015.

    By Mike Benson
  • uploads///Div Yield
    Company & Industry Overviews

    How Chevron’s Dividend Yield Has Trended

    Chevron’s dividend yield Chevron (CVX) has consistently given returns to shareholders in the form of dividends. Therefore, we have evaluated its dividend yields. Yield is calculated as a ratio of the annualized dividend to stock price. Chevron’s dividend yield rose from 3.3% in 4Q13 to 4.1% in 4Q16, due to a dividend increase coupled with […]

    By Maitali Ramkumar
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Consumer Segment

    Johnson & Johnson’s (JNJ) Consumer segment revenues fell 1.5% to ~$13.3 billion for 2016, compared to 2015.

    By Mike Benson
  • uploads///Div yields
    Company & Industry Overviews

    Inside ExxonMobil’s Dividend Yield

    ExxonMobil’s dividend yield rose from 2.8% in 4Q13 to 3.6% in 4Q16.

    By Maitali Ramkumar
  • uploads///Chart
    Company & Industry Overviews

    Understanding Pfizer’s Growth Contributors in 4Q16

    The key performers in Pfizer’s (PFE) product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis, which are in the company’s Innovative Health business.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Januvia and Janumet: Merck & Co.’s Blockbuster Diabetes Products

    Januvia and Janumet together contributed about 14.9% of Merck & Co.’s total revenues for 4Q16, an ~0.7% increase compared to 4Q15

    By Mike Benson
  • uploads///Dividend Yield
    Company & Industry Overviews

    XOM, CVX, RDS.A, BP: Who Has Better Dividend Yields?

    ExxonMobil (XOM), Chevron (CVX), Royal Dutch Shell (RDS.A), and BP (BP) have consistently given returns to shareholders in the form of dividends.

    By Maitali Ramkumar
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Consumer Segment’s 4Q16 Earnings

    Johnson & Johnson’s (JNJ) Consumer segment’s revenue rose 3.4% to $3.4 billion in 4Q16 compared to 4Q15. This rise included an operational rise of 4.9%.

    By Mike Benson
  • uploads///Cashflows
    Company & Industry Overviews

    What Does a Cash Flow Analysis of Valero Energy Reveal?

    Valero saw a rise in its cash balance in the first nine months of 2016. VLO’s cash balance in the period stood at $5.9 billion, showing a 12% rise over the first nine months of 2015.

    By Maitali Ramkumar
  • uploads///PART
    Company & Industry Overviews

    Which Assets Find Support in a Reflationary Environment?

    The focus can now shift to the assets that are more cyclical, like financials (XLF) (IYF), utilities (XLU) (IGF), and dividend growers.

    By Richard Turnill
  • uploads///Chart
    Company & Industry Overviews

    Merck Is Getting Serious about Animal Health

    Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. The global sales reported for 3Q16 totaled ~$865 million.

    By Mike Benson
  • uploads///Part  st
    Macroeconomic Analysis

    Are Dividend Growers a Better Option Than Dividend Payers?

    With a gradual increase in interest rates, dividend-growing companies have room to grow and can offer a higher yield with higher income. On the other hand, dividend-paying companies have no room for growth.

    By Terry Simpson
  • uploads///Graph
    Company & Industry Overviews

    Pfizer’s Xeljanz Expected to See Strong Growth Trends in 2016

    Pfizer’s (PFE) inflammation and immunology drug Xeljanz has seen strong growth trends in 2016, mainly due to high efficacy as a monotherapy and increasing brand awareness.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Aims to Position Avelumab as Backbone Immuno-Oncology Therapy

    On June 6, Pfizer and Merck announced positive results from a Phase 2 study testing Avelumab as a therapy for previously treated Merkel cell carcinoma.

    By Margaret Patrick
  • uploads///analyst recommendations
    Earnings Report

    What Do Analysts Say about JNJ after Its 3Q16 Results?

    Based on recommendations from 25 broker firms in a Bloomberg survey, Johnson & Johnson (JNJ) received “buy” ratings from ~44% of the firms, and ~56% of the firms rated the company a “hold.” None of the firms gave a “sell” rating to Johnson & Johnson.

    By Sarah Collins
  • uploads///Estimates
    Earnings Report

    Are Earnings Expectations for ExxonMobil Improving?

    ExxonMobil (XOM) is expected to post its 3Q16 results on October 28, 2016. In 2Q16, XOM’s revenues surpassed Wall Street estimates by 5%.

    By Maitali Ramkumar
  • uploads///eps estimates
    Earnings Report

    Could Johnson & Johnson’s Earnings Grow in 3Q16?

    Analysts’ estimates Johnson & Johnson (JNJ) accounts for ~6.3% of the total holdings of the iShares Core High Dividend ETF (HDV). The company has managed to exceed analysts’ earnings estimates for the last several quarters. The movement in a company’s share price is generally impacted by the deviation of its actual results from analysts’ estimates. Usually, a stock’s […]

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    What’s the Outlook for Pfizer?

    Analysts estimates The strong performance Pfizer’s (PFE) innovative products and the inclusion of the Hospira business have driven the company’s 2Q16 earnings, surpassing analysts’ estimates for revenues and EPS (earnings per share). Pfizer reported EPS of $0.64 on revenues of $13.2 billion in 2Q16, against the estimated EPS of $0.62 on revenues of $13.0 billion. Due […]

    By Mike Benson
  • uploads///lyrica
    Company & Industry Overviews

    How Pfizer’s Internal Medicine Core Drugs Are Performing

    The major contributors in Pfizer’s (PFE) Internal Medicine business include Lyrica and Viagra. Lyrica’s Innovative Health (or IH) contribution to the Internal Medicine portfolio stood at 48%.

    By Jillian Dabney
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads/// Div Growers
    Company & Industry Overviews

    Do Dividend Growers Look Appealing?

    Historically, dividend growers have often performed better than the S&P 500 (IVV) and provided higher income during Market volatility.

    By Richard Turnill
  • uploads///Chart
    Company & Industry Overviews

    Why Is Pfizer’s Valuation Low Compared to Its Peers?

    On August 8, 2016, Pfizer (PFE) was trading at a forward PE multiple of ~13.8x. The industry currently trades at a forward PE multiple of ~17.2x.

    By Mike Benson
  • uploads///Estimates
    Earnings Report

    How Did BP’s 2Q16 Earnings Stand up to Analyst Estimates?

    BP reported its 2Q16 earnings on July 26. Its revenues missed analyst estimates by 4%. It reported a loss of $0.46 in EPS, but adjusted EPS stood at $0.23.

    By Maitali Ramkumar
  • uploads///IH
    Earnings Report

    Petrobras’s Institutional Holdings, Pre-2Q16 Results

    Petrobras’s (PBR) institutional holdings currently stand at ~12%.

    By Maitali Ramkumar
  • uploads///IH
    Earnings Report

    Where Do HFC’s Institutional Holdings Stand Pre-Earnings?

    HollyFrontier’s (HFC) institutional holdings currently stand at ~98%.

    By Maitali Ramkumar
  • uploads///Estimates
    Earnings Report

    ExxonMobil’s 2Q Earnings Expected to Outshine 1Q Results

    According to Wall Street analysts’ estimates, ExxonMobil is expected to post earnings per share of $0.64 in 2Q16—36% lower than 2Q15’s adjusted EPS.

    By Maitali Ramkumar
  • uploads///Segments
    Earnings Report

    What to Expect from Suncor Energy’s Business Segments in 2Q16

    Suncor Energy’s (SU) Refining and Marketing segment’s operating earnings fell by 52% from 1Q15 to 241 million Canadian dollars in 1Q16.

    By Maitali Ramkumar
  • uploads///Q Inventory
    Consumer

    Analyzing Tobacco Companies’ 1Q16 Inventory Levels

    1Q16 inventory levels were lower for tobacco companies due to falling cigarette shipment volumes.

    By Penny Morgan
  • uploads///
    Company & Industry Overviews

    Analyzing Dominion Resources’ Forward Dividend Yield

    As of June 28, 2016, Dominion Resources is trading at a forward dividend yield of 3.7%. The three-year historical average for its forward dividend yield is 4%.

    By Vineet Kulkarni
  • uploads///Cash Flow
    Company & Industry Overviews

    Why Are BP’s Cash Reserves Plunging?

    In 1Q16, BP’s cash flow from operations stood at $1.9 billion, almost the same as in 1Q15. Its cash outflow from investing stood at $3.2 billion in 1Q16.

    By Maitali Ramkumar
  • uploads///Refining Index
    Company & Industry Overviews

    What Does Tesoro’s Refining Index Tell Us?

    In 2Q16 to date, Tesoro’s refining index values have risen compared to 1Q16 but have fallen compared to 2Q15. These values are regional crack indicators in the areas where TSO operates.

    By Maitali Ramkumar
  • uploads///Q EEMA Region
    Earnings Report

    Philip Morris’s 1Q16 Shipment Volume Declined in Russia

    PM’s increase in revenue on a constant currency basis was primarily due to favorable pricing of $0.1 billion, driven by Russia and Turkey, and partially offset by Ukraine.

    By Penny Morgan
  • uploads///Cash flow
    Company & Industry Overviews

    What Are the Roles of Debt and Dividends in Eni’s Cash Flow?

    In 2015, Eni’s (E) cash flow from operations stood at 12 billion euros, falling from 15 billion euros in 2014.

    By Maitali Ramkumar
  • uploads///Margins Q
    Company & Industry Overviews

    Why Did Beauty Companies’ Operating Margins Shrink in 4Q15?

    Beauty companies have been investing heavily in growth initiatives, which is impacting their margins.

    By Penny Morgan
  • uploads///Inventory Mgmt Q
    Macroeconomic Analysis

    How Can Tobacco Companies Improve 1Q16 Inventory Levels?

    Inventory levels for 4Q15 were lower for tobacco companies due to declining shipment volume of cigarettes. The overall cigarette industry volume declined 0.5% in 4Q15.

    By Penny Morgan
  • uploads///Q EEMA Region OV
    Earnings Report

    PM Is Increasing Prices in Russia due to the Weakening Ruble

    PM’s rise in revenue in Eastern Europe, the Middle East, and Africa was primarily due to favorable pricing driven by Russia, Turkey, and the Ukraine.

    By Penny Morgan
  • uploads///Annotated
    Earnings Report

    Chevron Closes Slightly Higher following Its 4Q15 Results

    Chevron announced its 4Q15 results on January 29, before the market opened. As Chevron missed its estimates for 4Q15, the stock received a weak opening.

    By Maitali Ramkumar
  • uploads///Telecom Spectrum Bought in FCC Auction
    Company & Industry Overviews

    AT&T Boosted Its Mid-Band Spectrum Portfolio in 2015

    AT&T completed a ~$18.2 billion transaction of AWS-3 spectrum holdings during 1Q15. It bought these spectrum holdings at the FCC’s AWS-3 spectrum auction.

    By Ray Sheffer
  • uploads///Telecom Per Line Maximum Amount in Prepaid Card For Customers Switching From Other Carriers
    Company & Industry Overviews

    Verizon’s Wireless Promotional Efforts

    Verizon’s Marni Walden discussed how the move from traditional subsidy models to installment plans may be affecting the company’s promotional efforts.

    By Ray Sheffer
  • uploads///Margins
    Macroeconomic Analysis

    Consumer Packaged Goods Companies Saw Improved Margins

    CPG companies’ 3Q15 margins sent strong signals. They have been investing in innovative products and other growth initiatives. This is impacting their margins.

    By Penny Morgan
  • uploads///Telecom Verizon Edge Take Rate
    Company & Industry Overviews

    Analyzing the Potential Growth of Verizon’s Installment Plans

    Sequentially, the take rate of Verizon’s installment plans has been increasing evenly.

    By Ray Sheffer
  • uploads///fdedfcfdabdddca
    Company & Industry Overviews

    Analyzing Verizon’s Value Proposition in the US Telecom Space

    Verizon’s average five-year dividend yield is ~4.7%, which is slightly lower than AT&T’s dividend yield of ~5.4%.

    By Ray Sheffer
  • uploads///Telecom Verizon Connections Frontier Deal
    Company & Industry Overviews

    What’s Happening with Verizon’s Wireline Asset Sale to Frontier?

    In this series, we will look at some key points that Verizon (VZ) discussed at the recent UBS Global Media and Communications Conference on December 7, 2015.

    By Ray Sheffer
  • uploads///Part
    Company & Industry Overviews

    What Are the Key Factors that Drive Upstream Costs?

    With crude oil prices declining in 2014, integrated energy companies have lowered their E&P capital expenditures.

    By Maitali Ramkumar
  • uploads///USIO revenue
    Earnings Report

    What Led Cliffs to Increase Its Realized Revenues for US Iron Ore?

    Cliffs Natural Resources’ (CLF) realized revenues from USIO (or US iron ore division) were lower than expected.

    By Anuradha Garg
  • uploads///part
    Earnings Report

    Is the Market Underestimating Nucor’s Earnings Capacity?

    In this series, we’ll analyze Nucor’s 3Q15 earnings and explore the factors that drove its financial performance amid challenging steel market conditions.

    By Mohit Oberoi, CFA
  • uploads///EEMA Region
    Earnings Report

    Why Philip Morris’s EEMA Region Saw Revenue Wobbles in 3Q15

    Philip Morris’s 3Q15 revenues from the EEMA region decreased by 13.8% to $2.1 billion due to an unfavorable currency impact of $0.6 billion.

    By Penny Morgan
  • uploads///Screenshot
    Earnings Report

    How Did Intel’s Business Segments Perform?

    Intel operates through four major business segments—Client Computing Group, Data Center Group, Internet of Things Group, and Software and Services Group.

    By Puja Tayal
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.